New alternative therapeutical strategies in early senescence and immunosenescence

The patients will be randomly divided in five different subgroups, checking afterwards that there are not any significant differences between the groups, regarding their age, sex, neuroimagistic findings, and their cognitive status reflected by Mini Mental State Examination (MMSE) scores. The mini–mental state examination (MMSE) is a brief 30-point questionnaire test that is used to screen for cognitive impairment. It is used to estimate the severity of cognitive impairment and to follow the course of cognitive changes in an individual over time, thus making it an effective way to document an individual's response to treatment. The subgroups will receive the treatment orally, for at least one year, to a maximum duration of two years. The overall duration of treatment will be decided after the subject's assessment at one year, upon completing the evaluation tests performed at that time. The study subgroups will receive the treatment as follows: 1. subgroup A that will comprise elderly subjects diagnosed with mild cognitive impairment (MCI), having the MMSE score between 21-28 points). This subgroup will be treated with Piracetam 4 tablets/day (daily dose: 1600 mg); 2. subgroup B that will comprise elderly subjects diagnosed with MCI, that will be treated with Rhodiola-rosea, 2 capsules/day (500 mg daily); 3. subgroup C that will comprise elderly subjects diagnosed with MCI,which will be treated with Selezin ACE (Selenium 100 mcg, Zinc 15 mg; Vitamin A 1000 mcg, Vitamin B6 2,20 mg, Vitamin C 90 mg, Vitamin E 15 mg) and Coenzyme Q (10 mg daily); 4. subgroup D that will comprise elderly subjects with MCI, treated with Selezin ACE, Coenzyme Q (10 mg daily) and Rhodiola Rosea (500 mg daily).